INM | InMed Pharmaceuticals Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.14 - 4.51
52 Week Range	2.4200 - 15.70
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	40,893
Average Volume	39,302
Shares Outstanding	718,032
Market Cap	3,158,479
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-05-05

Valuation
Profitability
Growth
Health
P/E Ratio	0.02
Forward P/E Ratio	-0.10
EPS	230.40
1YR Price Target	45.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	13
Country	Canada
Website	INM

InMed Pharmaceuticals Inc is a Canada based pre-clinical stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based therapies combined with drug delivery systems. It is focused on the treatment of diseases including pain and inflammation, dermatology, Orofacial Pain, Glaucoma, ocular, CNS, respiratory, metabolic diseases, and others.

INM's peers: CYCCP, QNRX, ALLR, KRBP, VRAX, BDRX, ICU, VIRI, ZVSA, SONN, REVB, PALI, DRUG, TNXP, IMMX, PHIO, ATNF, NAVB, SGTX, NBY, GOVX, VTVT

*Chart delayed

Analyzing fundamentals for INM we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see INM Fundamentals page.

Watching at INM technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on INM Technicals page.